Hide metadata

dc.date.accessioned2024-01-12T17:59:27Z
dc.date.available2024-01-12T17:59:27Z
dc.date.created2024-01-02T12:20:40Z
dc.date.issued2023
dc.identifier.citationRai, Anam Shakil Sletner, Line Jenum, Anne Karen Øverby, Nina Cecilie Stafne, Signe Nilssen Qvigstad, Elisabeth Pripp, Are Hugo Sagedal, Linda Reme . Employing fasting plasma glucose to safely limit the use of oral glucose tolerance tests in pregnancy: a pooled analysis of four Norwegian studies. Frontiers in Endocrinology. 2023, 14
dc.identifier.urihttp://hdl.handle.net/10852/106763
dc.description.abstractBackground/objective There is no international consensus about the optimal approach to screening and diagnosis of gestational diabetes mellitus (GDM). Fasting plasma glucose (FPG) has been proposed as an alternative universal screening test to simplify the diagnosis of GDM. We investigate the ability of the FPG to predict a 2-hour glucose value below the cut-off for GDM, thereby “ruling out” the necessity of a full OGTT and assess the proportion of GDM-related complications associated with the identified FPG level. Materials and methods This study included secondary data from four Norwegian pregnancy cohorts (2002-2013), encompassing 2960 women universally screened with late mid-pregnancy 75g OGTT measuring FPG and 2-hour glucose. For a range of FPG thresholds, we calculated sensitivity to predict elevated 2-hour glucose, number of OGTTs needed and percentage of GDM cases missed, applying modified World Health Organization (WHO) 2013 criteria ( 2013 WHO) and 2017 Norwegian criteria ( 2017 Norwegian). We analyzed pregnancy outcomes for women above and below our selected threshold. Results The prevalence of GDM was 16.6% ( 2013 WHO) and 10.1% ( 2017 Norwegian). A FPG threshold of 4.7 mmol/L had a sensitivity of 76% ( 2013 WHO) and 80% ( 2017 Norwegian) for detecting elevated 2-hour glucose, with few missed GDM cases (2.0% of those ruled out and 7.5% of all GDM cases for 2013 WHO, and 1.1% of those ruled out and 7% of all GDM cases for 2017 Norwegian). When excluding women with FPG <4.7mmol/l and those with GDM based on FPG, only 24% ( 2013 WHO) and 29% ( 2017 Norwegian) would require OGTT. Women with FPG <4.7mmol/l, including missed GDM cases, had low risk of large-for-gestational-age newborns, cesarean section and operative vaginal delivery. Conclusion A FPG threshold of 4.7mmol/l as a first step when screening for GDM could potentially eliminate the need for OGTT in 70-77% of pregnancies. Women with FPG below this threshold appear to carry low risk of GDM-associated adverse pregnancy outcomes.
dc.languageEN
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.titleEmploying fasting plasma glucose to safely limit the use of oral glucose tolerance tests in pregnancy: a pooled analysis of four Norwegian studies
dc.title.alternativeENEngelskEnglishEmploying fasting plasma glucose to safely limit the use of oral glucose tolerance tests in pregnancy: a pooled analysis of four Norwegian studies
dc.typeJournal article
dc.creator.authorRai, Anam Shakil
dc.creator.authorSletner, Line
dc.creator.authorJenum, Anne Karen
dc.creator.authorØverby, Nina Cecilie
dc.creator.authorStafne, Signe Nilssen
dc.creator.authorQvigstad, Elisabeth
dc.creator.authorPripp, Are Hugo
dc.creator.authorSagedal, Linda Reme
cristin.unitcode185,52,15,0
cristin.unitnameAvdeling for allmennmedisin
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.cristin2218856
dc.identifier.bibliographiccitationinfo:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Frontiers in Endocrinology&rft.volume=14&rft.spage=&rft.date=2023
dc.identifier.jtitleFrontiers in Endocrinology
dc.identifier.volume14
dc.identifier.pagecount0
dc.identifier.doihttps://doi.org/10.3389/fendo.2023.1278523
dc.type.documentTidsskriftartikkel
dc.type.peerreviewedPeer reviewed
dc.source.issn1664-2392
dc.type.versionPublishedVersion
cristin.articleid1278523


Files in this item

Appears in the following Collection

Hide metadata

Attribution 4.0 International
This item's license is: Attribution 4.0 International